Please login to the form below

Not currently logged in
Email:
Password:

Catabasis hires Rick Modi as its chief business officer

Will help the firm develop its flagship Duchenne muscular dystrophy product

The US biotech firm Catabasis Pharmaceuticals has named Rick Modi as its new chief business officer. 

Modi brings to Catabasis 15 years of experience in corporate, business and product commercialisation strategy.

Jill Milne, co-founder and chief executive of Catabasis, said: “Rick has valuable experience across multiple brands, including orphan drug positioning, commercialisation and marketing. 

“We look forward to leveraging his capabilities as we advance our clinical development pipeline, particularly CAT-1004 for Duchenne muscular dystrophy (DMD), and our lipid programmes, CAT-2003 and CAT-2054.”

Modi added: “Catabasis has a novel approach to drug development that allows for simultaneous modulation of multiple targets in a disease pathway, and I am privileged to join this team as we seek to bring disease-modifying treatments to patients with DMD or severe lipid disorders."

Prior to joining Catabasis, Modi was senior vice president, global marketing at InterMune - an orphan drug company that was acquired by Roche late last year.

He played a large role in the launch of InterMune's flagship product, the lung-scarring drug Esbriet (pirfenidone)

Modi has also held roles of increasing responsibilities in corporate strategy, new product planning and sales and marketing at AstraZeneca's biologics arm MedImmune as well as J&J's subsidiary Centocor.

16th February 2015

From: Research, Healthcare

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics